Clinical Trial

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. In gene therapy, small stretches of deoxyribonucleic acid (DNA) called "anti-HIV genes" are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2016-06-08; most recent amendment 2026-05-04.
Status change: Recruiting → Active, Not Recruiting 2023-05-26
Status change: Suspended → Recruiting 2018-01-02
Status change: Recruiting → Suspended 2017-07-14
Trial Details
NCT Number NCT02797470
Lead Sponsor AIDS Malignancy Consortium
Collaborators: National Cancer Institute (NCI), California Institute for Regenerative Medicine (CIRM)
Conditions HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma +3 more
Enrollment 11 participants
Start Date 2016-06-23
Primary Completion 2021-05-13 (estimated)
Study Completion 2036-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-18